Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Atea Pharmaceuticals ( (AVIR) ) is now available.
On February 20, 2025, Atea Pharmaceuticals appointed Arthur Kirsch as a Class I director. Mr. Kirsch brings extensive experience from his roles in investment banking and advisory positions in the healthcare and life sciences sectors, which the company believes will enhance its strategic direction. His compensation includes an annual cash retainer and equity awards, reflecting Atea’s commitment to leveraging his expertise for future growth.
More about Atea Pharmaceuticals
Atea Pharmaceuticals operates in the healthcare and life sciences industry, focusing on developing and commercializing antiviral therapies.
YTD Price Performance: -9.65%
Average Trading Volume: 424,661
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $261M
Learn more about AVIR stock on TipRanks’ Stock Analysis page.